A study published in the Journal of Crohn’s and Colitis found that the efficacy of biologic therapy for inflammatory bowel disease (IBD) in adults can be extrapolated to adolescents. Data from 11 placebo-controlled trials of biologic therapies were analyzed, showing favorable outcomes for both adolescent- and adult-onset IBD. Pediatric gastroenterologists often prescribe advanced IBD therapies for adolescents based on efficacy data from adult studies. While there were some differences in response to specific therapies between adolescent- and adult-onset disease, overall outcomes were similar. The study was supported by Johnson & Johnson Innovative Medicine. More research is needed due to the small proportion of patients with adolescent-onset disease.
Source link
Do Biologics Have Similar Efficacy?
